Improved Persistence to Medication, Decreased Cardiovascular Events and Reduced All-Cause Mortality in Hypertensive Patients With Use of Single-Pill Combinations: Results From the START-Study

被引:26
|
作者
Schmieder, Roland E. [2 ]
Wassmann, Sven [3 ,4 ]
Predel, Hans-Georg [5 ]
Weisser, Burkhard [6 ]
Blettenberg, Joerg [7 ]
Gillessen, Anton [8 ]
Randerath, Olaf [1 ,9 ]
Mevius, Antje [10 ]
Wilke, Thomas [10 ]
Boehm, Michael [11 ]
机构
[1] APONTIS Pharm GmbH & Co KG, Alfred Nobel Str 10, D-40789 Monheim, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Nephrol & Hypertens, Erlangen, Germany
[3] Fac Med, Cardiol Pasing, Munich, Germany
[4] Univ Saarland, Homburg Saar, Germany
[5] German Sport Univ Cologne, Inst Cardiol & Sports Med, Cologne, Germany
[6] Christian Albrechts Univ Kiel, Inst Sports Sci, Kiel, Germany
[7] Practice Dr J Blettenberg, Lindlar, Germany
[8] Herz Jesu Hosp, Dept Internal Med, Munster, Germany
[9] APONTIS Pharm Deutschland GmbH & Co, Med Dept, Monheim, Germany
[10] Inst Pharmakookon & Arzneimittellogist IPAM, Wismar, Germany
[11] Saarland Univ, Univ klinikum Saarlandes, Klin Innere Med 3, Homburg Saar, Germany
关键词
antihypertensive agents; cardiovascular diseases; hypertension; medication adherence; mortality; prognosis; risk factors; ANTIHYPERTENSIVE DRUG-TREATMENT; THERAPY CONTROVERSIES; ADHERENCE; RISK; METAANALYSIS; PREVALENCE; SOCIETY; IMPACT; SIDE;
D O I
10.1161/HYPERTENSIONAHA.122.20810
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
BACKGROUND: Single-pill combination improves adherence and persistence to medication in hypertension. It remains unclear whether this also reduces cardiovascular outcomes and all-cause mortality. We analyzed whether single-pill combinations are superior to identical multiple pills on persistence to medication, cardiovascular outcomes, and all-cause mortality. METHODS: This was a retrospective claims data (German AOK PLUS) analysis. Data from hypertensive patients >= 18 years treated with renin-angiotensin system combinations given as single pill or identical multipills covering the years 2012 to 2018 were analyzed and followed up to at least 1 year. After 1:1 propensity score matching, persistence to medication, cardiovascular events, and all-cause mortality were compared using non-parametric tests. Results were reported as incidence rate ratios and hazard ratios. RESULTS: After propensity score matching data from 57 998 patients were analyzed: 10 801 patients received valsartan/amlodipine, 1026 candesartan/amlodipine, 15 349 ramipril/amlodipine, and 1823 amlodipine/valsartan/hydrochlorothiazide as single pill or identical multipill. No relevant differences in patient characteristics were observed within the 4 groups. In all groups, a significant lower all-cause mortality, a significant a higher persistence to medication, a significant lower event rate in 15 out of 20 comparisons, and a tendency in the remaining 5 comparisons was observed under single pills compared with multipill combinations. CONCLUSIONS: Antihypertensive combination therapy reduces all-cause mortality and cardiovascular when provided as single pill compared to identical drugs as multipills. This strongly supports the European Society of Cardiology/European Society of Hypertension and International Society of Hypertension guidelines recommending the use of a single-pill combination and thus should be more rigorously implemented into daily clinical practice.
引用
收藏
页码:1127 / 1135
页数:9
相关论文
共 24 条
  • [1] THE SINGLE PILL CONCEPT LEADS TO IMPROVED PERSISTENCE OF MEDICATION, CLINICAL OUTCOMES AND REDUCED ALL-CAUSE MORTALITY IN HYPERTENSIVE PATIENTS - RESULTS FROM THE START PROJECT
    Predel, Hans-Georg
    Weisser, Burkhard
    Wassmann, Sven
    Gillessen, Anton
    Blettenberg, Joerg
    Fournier, Valerie
    Noetel, Andrea
    Randerath, Olaf
    Boehm, Michael
    Schmieder, Roland E.
    JOURNAL OF HYPERTENSION, 2021, 39 : E378 - E378
  • [2] Single pill treatment in daily practice is associated with improved clinical outcomes and all-cause mortality in cardiovascular diseases: results from the START project
    Weisser, B.
    Wilke, T.
    Predel, H. G.
    Schmieder, R. E.
    Wassmann, S.
    Gillessen, A.
    Blettenberg, J.
    Maywald, U.
    Randerath, O.
    Mevius, A.
    Boehm, M.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2254 - 2254
  • [3] Real-world analysis exploring the association between anti-hypertensive therapy with perindopril-based single-pill combinations (SPC) and cardiovascular outcomes and all-cause mortality in Italy
    Wolf, J.
    Magne, J.
    Masi, S.
    Vintila, A. M.
    Dovizio, M.
    Nugnes, M.
    Veronesi, C.
    Degli Esposti, L.
    Savarese, G.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [4] All-cause mortality, cardiovascular mortality, major cardiovascular events and hypoglycaemia of patients with diabetes onset at an older age: results from the 10-year nationwide cohort study
    Chou, Ming-Yueh
    Huang, Shih-Tsung
    Liang, Chih-Kuang
    Peng, Li-Ning
    Lin, Yu-Te
    Hsiao, Fei-Yuan
    Chen, Liang-Kung
    AGE AND AGEING, 2021, 50 (06) : 2094 - 2104
  • [5] Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study
    Kim, Dae Jung
    Sheu, Wayne H-H
    Chung, Wook-Jin
    Yabe, Daisuke
    Ha, Kyoung Hwa
    Nangaku, Masaomi
    Tan, Elise Chia-Hui
    Node, Koichi
    Yasui, Atsutaka
    Lei, Weiyu
    Lee, Sunwoo
    Saarelainen, Laura
    Deruaz-Luyet, Anouk
    Kyaw, Moe H.
    Seino, Yutaka
    EMPRISE East Asia Study Grp
    JOURNAL OF DIABETES INVESTIGATION, 2023, 14 (03) : 417 - 428
  • [6] β-Blocker use and all-cause mortality of melanoma patients: Results from a population-based Dutch cohort study
    Livingstone, E.
    Hollestein, L. M.
    van Herk-Sukel, M. P. P.
    van de Poll-Franse, L.
    Nijsten, T.
    Schadendorf, D.
    de Vries, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (18) : 3863 - 3871
  • [7] Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study
    Colman Siu Cheung Fung
    Eric Yuk Fai Wan
    Anca Ka Chun Chan
    Cindy Lo Kuen Lam
    BMC Cardiovascular Disorders, 17
  • [8] Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study
    Fung, Colman Siu Cheung
    Wan, Eric Yuk Fai
    Chan, Anca Ka Chun
    Lam, Cindy Lo Kuen
    BMC CARDIOVASCULAR DISORDERS, 2017, 17
  • [9] Metformin treatment is associated with reduced risk of hypoglycaemia, major adverse cardiovascular events, and all-cause mortality in patients with post-pancreatitis diabetes mellitus: a nationwide cohort study
    Davidsen, Line
    Jensen, Morten H.
    Cook, Mathias E.
    Vestergaard, Peter
    Knop, Filip K.
    Drewes, Asbjorn M.
    Olesen, Soren S.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2024, 190 (01) : 44 - 53
  • [10] DETERMINANTS OF LONG-TERM ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN HYPERTENSIVE PATIENTS - FINDINGS FROM 16-YEAR FOLLOW-UP OF THE ASCOT LEGACY STUDY
    Gupta, A.
    Mackay, J.
    Whitehouse, A.
    Godec, T.
    Collier, T.
    Poulter, N.
    Sever, P.
    JOURNAL OF HYPERTENSION, 2018, 36 : E27 - E27